Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T E Stinchcombe

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2021
Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancerT E Stinchcombe
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2017
Biomarker-directed molecularly targeted therapy: the importance of prospective evaluationT E Stinchcombe
Current Opinion in Oncology|May 18, 1999
Renal cell carcinomaP A Godley, T E Stinchcombe
Oncogene|May 29, 2007
Bevacizumab in the treatment of non-small-cell lung cancerT E Stinchcombe, M A Socinski
British Journal of Haematology|September 1, 2001
The dysfibrinogenaemiasH R Roberts, T E Stinchcombe, D A Gabriel
ESMO Open|March 11, 2023
A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutationsL C Villaruz, X Wang, E M Bertino, et al.
Clinical Pharmacology and Therapeutics|May 1, 2014
Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analysesM A Phelps, T E Stinchcombe, J S Blachly, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2021
Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancerT E Stinchcombe
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2017
Biomarker-directed molecularly targeted therapy: the importance of prospective evaluationT E Stinchcombe
Current Opinion in Oncology|May 18, 1999
Renal cell carcinomaP A Godley, T E Stinchcombe
Oncogene|May 29, 2007
Bevacizumab in the treatment of non-small-cell lung cancerT E Stinchcombe, M A Socinski
British Journal of Haematology|September 1, 2001
The dysfibrinogenaemiasH R Roberts, T E Stinchcombe, D A Gabriel
ESMO Open|March 11, 2023
A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutationsL C Villaruz, X Wang, E M Bertino, et al.
Clinical Pharmacology and Therapeutics|May 1, 2014
Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analysesM A Phelps, T E Stinchcombe, J S Blachly, et al.
Pageof 1